The project on high-risk Acute Promyelocytic Leukemia (APL) is a comprehensive research endeavor that combines proteomics and genomics to gain a deeper understanding of acquired arsenic trioxide (ATO) resistance. With the use of different APL models together with novel therapeutic combinations, we aim to overcome ATO resistance.